ALPS Advisors’s Axsome Therapeutics AXSM Stock Holding History

ALPS Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-24,437	Closed	-$2.97M	–	1020
2025 Q3	$2.97M	Sell	24,437 -2,095	-8%	-$236K	0.02%	328
2025 Q2	$2.77M	Sell	26,532 -5,832	-18%	-$618K	0.02%	322
2025 Q1	$3.77M	Sell	32,364 -6,826	-17%	-$778K	0.02%	267
2024 Q4	$3.32M	Buy	+39,190	New	+$3.6M	0.02%	275
2024 Q2	–	Sell	-33,417	Closed	-$2.67M	–	970
2024 Q1	$2.67M	Buy	33,417 +935	+3%	+$78.5K	0.02%	308
2023 Q4	$2.59M	Sell	32,482 -2,346	-7%	-$157K	0.02%	303
2023 Q3	$2.43M	Buy	34,828 +2,800	+9%	+$209K	0.02%	294
2023 Q2	$2.3M	Buy	32,028 +3,353	+12%	+$247K	0.02%	286
2023 Q1	$1.77M	Sell	28,675 -748	-3%	-$49.1K	0.02%	313
2022 Q4	$2.27M	Buy	+29,423	New	+$1.76M	0.02%	279

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ALPS Advisors's AXSM Position: Q4 2025 in Review

ALPS Advisors sold out of Axsome Therapeutics (AXSM) in Q4 2025, closing a stake of 24,437 shares — an estimated $2.97M sold.

ALPS Advisors first reported a position in AXSM in Q4 2022 and held it in 10 quarters. The position peaked at $3.77M in Q1 2025. 398 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

ALPS Advisors reported no remaining Axsome Therapeutics position as of Q4 2025 after selling out during the quarter.
ALPS Advisors sold 24,437 Axsome Therapeutics shares in Q4 2025, an estimated $2.97M.
ALPS Advisors first reported a position in Axsome Therapeutics in Q4 2022 and held it in 10 quarters.
ALPS Advisors's Axsome Therapeutics position peaked at $3.77M in Q1 2025.
398 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on ALPS Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.